
Licensing Agreements for CRISPR/Cas9 Genome Editing Technology Patent
Curator: Aviva Lev-Ari, PhD, RN
AstraZeneca’s CRISPR research collaborations are with the following institutions:
The Wellcome Trust Sanger Institute, Cambridge, UK
Under the terms of the collaboration with the Wellcome Trust Sanger Institute, research will focus on deleting specific genes relevant to cancer, cardiovascular, metabolic, respiratory, autoimmune & inflammatory diseases and regenerative medicine to understand their precise role in these conditions. AstraZeneca will provide cell lines that can be targeted using the Sanger Institute’s collection of genome-wide CRISPR guide-RNA libraries to generate populations of cells in which defined genes are switched off. Genes will subsequently be identified by next-generation sequencing and cell populations tested to validate the effects of a given gene on a wide range of physical and biological traits.
“The Sanger Institute’s guide-RNA library enables researchers to target genes with incredible specificity,” said Dr. Kosuke Yusa, Member of Faculty at the Sanger Institute. “CRISPR has transformed the way we study the behaviour of cells and now the application of this powerful technology to the search for effective drugs has the potential to benefit patients.”
The Innovative Genomics Initiative, California
The Innovative Genomics Initiative (IGI) is a joint venture between the University of California, Berkeley and University of California, San Francisco. The research collaboration will focus on either inhibiting (CRISPRi) or activating (CRISPRa) genes to understand their role in disease pathology. The IGI and AstraZeneca will work closely together to identify and validate gene targets relevant to cancer, cardiovascular, metabolic, respiratory, autoimmune and inflammatory diseases and regenerative medicine to understand their precise role in these conditions.
“We are excited to pair the IGI’s premier expertise in CRISPR gene editing and regulation with AstraZeneca’s deep experience in therapeutics,” said Jacob Corn, Scientific Director of the Innovative Genomics Initiative. “I’m confident that, working side-by-side with scientists at AstraZeneca, our collaboration will positively impact drug discovery and development to hasten treatments to patients.”
Thermo Fisher Scientific, Waltham, Massachusetts
Under the terms of the collaboration with Thermo Fisher Scientific, a world-leading reagent and instrument provider, AstraZeneca will receive RNA-guide libraries that target individual known human genes and gene families. AstraZeneca can screen these guides against cell lines to identify new disease targets.
“Through this research collaboration with AstraZeneca, Thermo Fisher is helping to accelerate access to cutting edge genome-editing applications for next generation drug discovery. Enabling more relevant disease models will improve target identification and translation to therapeutics,” said Dr. Jon Chesnut, Director of Synthetic Biology R&D at Thermo Fisher Scientific.
Broad Institute/Whitehead Institute, Cambridge, Massachusetts
The collaboration with the Broad Institute and Whitehead Institute will evaluate a genome-wide CRISPR library against a panel of cancer cell lines with a view to identifying new targets for cancer drug discovery.
In addition to the new collaborations, AstraZeneca’s in-house programme is currently adapting CRISPR technology to streamline and accelerate the production of cell lines and translational models that mimic complex genomic and disease-relevant scenarios.
“Application of the CRISPR technology for precise genome editing in recombinant cell lines and in relevant disease models should enable us to identify novel targets, build better test systems for drug discovery and enhance the translatability of our efficacy and safety models,” said Dr. Lorenz Mayr, Vice President, Reagents & Assay Development, AstraZeneca.
The short video above explaining how CRISPR technology works is available in English, Mandarin and Spanish, and a still image illustrating the technology is available.
Download broadcast video and high-resolution image
About The Wellcome Trust Sanger Institute
The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.http://www.sanger.ac.uk/
About Innovative Genomics Initiative
The Innovative Genomics Initiative (IGI) was established in early 2014 at the Li Ka Shing Center for Genomic Engineering at the University of California, Berkeley, and is a joint UC Berkeley/UC San Francisco initiative catalyzing and guiding the global effort in both the academic and commercial research communities to unleash the transformative potential of CRISPR/Cas9 technology for positive human impact.
About the Broad Institute of Harvard and MIT
The Eli and Edythe L. Broad Institute of Harvard and MIT was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods and data openly to the entire scientific community.
Founded by MIT, Harvard and its affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to http://www.broadinstitute.org.
About Whitehead Institute
Whitehead Institute is a world-renowned non-profit research institution dedicated to improving human health through basic biomedical research. Wholly independent in its governance, finances, and research programs, Whitehead shares a close affiliation with Massachusetts Institute of Technology through its faculty, who hold joint MIT appointments. http://wi.mit.edu
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our four premier brands – Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
SOURCE
Novartis
- Caribou BioSciences – Jennifer Daudna
- Intellia
Novartis bought in to Intellia–as well as Caribou, which out-licensed some pioneering CRISPR tech created by Jennifer Doudna at UC Berkeley–with a clear interest in tapping the science for its ambitious CAR-T work reengineering T cells into cancer weapons. John Leonard was wooed in from the Big Pharma world, after a stint in charge of R&D at AbbVie ($ABBV). And gene editing–deleting, repairing and inserting genetic information to correct an ailment–has what is widely viewed as a potent future in devising a new generation of potential cures.
“CRISPR/Cas9 technology has potential to transform medicine by addressing previously untreatable genetic targets and serving as the basis for new and better therapies,” said Leonard in a statement. “This novel technology could potentially eliminate many severely disabling and life-threatening diseases for patients.”
But after the Big Vision, detailed insights into the company’s plans can be hard to glean. Asked about the apparent likelihood of an IPO in the offing, CEO Nessan Bermingham declined comment.
SOURCE
Novartis adopts a CRISPR-Cas9 partner and jumps into the hot new R&D field
A biotech war is brewing over control of the revolutionary CRISPR-Cas9 tech
Top research institutions hand hot gene-editing tech–with a catch–to Editas
Novartis joins Atlas in launching a CRISPR Cas biotech with a $15M bankroll
SOURCE
Bayer LifeScience Center (BLSC)
- ERS Genomics – Emmanuelle Charpentier
- CRISPR Therapeutics – Emmanuelle Charpentier and
Bayer Inks CRISPR Patent Licensing Agreement
NEW YORK (GenomeWeb) – Bayer and ERS Genomics announced today that they have signed a patent license agreement, giving the Bayer LifeScience Center (BLSC) access to ERS’s foundational CRISPR/Cas9 genome editing technology.
Financial and other details of the agreement were not disclosed.
ERS Genomics was formed to commercialize patents held by CRISPR pioneer Emmanuelle Charpentier, now director of the Max Planck Institute for Infection Biology. She is a co-inventor on a foundational CRISPR/Cas9 patent application currently at the center of a patent interference trial being conducted by the US Patent and Trademark Office. A team led by the Broad Institute currently holds the key patent for CRISPR/Cas9 technology.
The BLSC has also recently created a joint venture with CRISPR Therapeutics, a firm Charpentier co-founded, to develop new CRISPR-based therapies.
SOURCE
https://www.genomeweb.com/business-news/bayer-inks-crispr-patent-licensing-agreement
Vertex Therapeutics
- CRISPR Therapeutics – Emmanuelle Charpentier
IDT
- Caribou BioSciences – Jennifer Daudna
DuPont
- Caribou BioSciences – Jennifer Daudna
Evotec
- Broad Institute
Regeneron
- ERS Genomics – Emmanuelle Charpentier
- Intellia – Jennifer Daudna
Licensing deal with Regeneron to accelerate CRISPR biotech Intellia (Jennifer Doudna’s Start Up) for an IPO
Reporter: Aviva Lev-Ari, PhD, RN
Albany Molecular Research (AMRI)
- Broad Institute
MERCK
- Moderna Therapeutics
Cases in Biotech Entrepreneurship: Selective Start Ups in 2016
Reporter: Aviva Lev-Ari, PhD, RN
Moderna Therapeutics Deal with Merck: Are Personalized Vaccines here?
Curator & Reporter: Stephen J. Williams, Ph.D.
at #JPM16 – Moderna Therapeutics turns away an extra $200 million: with AstraZeneca (collaboration) & with Merck ($100 million investment)
Reporter: Aviva Lev-Ari, PhD, RN
Leave a Reply